Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion.

Brentuximab vedotin (BV) is a drug that has improved outcomes in classical Hodgkin lymphoma (cHL). However, its safety and efficacy in patients living with HIV who present with severe liver failure and life-threating cytopenias is unclear. Here, we describe the case of a woman living with HIV diagnosed with cHL and how she recovered from a hemoglobin nadir of 24 g/L despite declining transfusion support and a bilirubin peak of 417.

Extensive Tracking of Nomadic Waterbird Movements Reveals an Inland Flyway.

Waterbirds are highly mobile and have the ability to respond to environmental conditions opportunistically at multiple scales. Mobility is particularly crucial for aggregate-nesting species dependent on breeding habitat in arid and semi-arid wetlands, which can be ephemeral and unpredictable. We aimed to address knowledge gaps about movement routes for aggregate-nesting nomadic waterbird species by tracking them in numbers sufficient to make robust assessment of their movement patterns.

Satellite telemetry reveals complex mixed movement strategies in ibis and spoonbills of Australia: implications for water and wetland management.

Waterbird population and species diversity maintenance are important outcomes of wetland conservation management, but knowledge gaps regarding waterbird movements affect our ability to understand and predict waterbird responses to management at appropriate scales. Movement tracking using satellite telemetry is now allowing us to fill these knowledge gaps for highly mobile waterbirds at continental scales, including in remote areas for which data have been historically difficult to acquire. We used GPS satellite telemetry to track the movements of 122 individuals of three species of ibis and spoonbills (Threskiornithidae) in Australia from 2016 to 2023.

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation.

Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first US Food and Drug Administration (FDA)-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT). Using Center for International Blood and Marrow Transplant Research data, we investigated its impact in patients receiving 7/8 HLA-mismatched unrelated donor (MMUD) or 8/8 HLA-matched unrelated donor (MUD) URD-HCT between 2011 and 2018. Primary outcomes included day-180, 1-year, and 2-year overall survival (OS) and relapse-free survival (RFS) for abatacept + CNI/MTX vs CNI/MTX, CNI/MTX + antithymocyte globulin (ATG), and posttransplant cyclophosphamide-based prophylaxis (PT-Cy).